Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Koeller DR, Manning DK, Schwartz A, Chittenden A, Hayes CP, Abraamyan F, et al. An optimized protocol for evaluating pathogenicity of VHL germline variants in patients suspected with von Hippel-Lindau syndrome: Using somatic genome to inform the role of germline variants. MethodsX. 2022;9:101761.

Hao Y, Yang HS, Karbaschi M, Racine-Brzostek SE, Li P, Zuk R, et al. Measurements of SARS-CoV-2 antibody dissociation rate constant by chaotrope-free biolayer interferometry in serum of COVID-19 convalescent patients. Biosens Bioelectron. 2022;209:114237.

Argani P, Boyraz B, Oliva E, Matoso A, Gross J, Fridman E, et al. GLI1 Gene Alterations in Neoplasms of the Genitourinary and Gynecologic Tract. Am J Surg Pathol. 2022;46(5):677-687.

Wang X, Barrera C, Bera K, Viswanathan VS, Azarianpour-Esfahani S, Koyuncu C, et al. Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors. Sci Adv. 2022;8(22):eabn3966.

Slocum CC, Park HJ, Baek I, Catalano J, Wells MT, Liechty B, et al. Towards a single-assay approach: a combined DNA/RNA sequencing panel eliminates diagnostic redundancy and detects clinically-relevant fusions in neuropathology. Acta Neuropathol Commun. 2022;10(1):167.

Greenberg J, Limberg J, Verma A, Kim D, Chen X, Lee YJ, et al. Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration. JCI Insight. 2022;7(23).

Kim S, Au CM, Bin Jamalruddin MA, Abou-Ghali NE, Mukhtar E, Portella L, et al. AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer. Elife. 2022;11.

Nassar AH, Adib E, Alaiwi SA, Zarif TE, Groha S, Akl EW, et al. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell. 2022;40(10):1161-1172.e5.

Lebowitz E, Kim JS, Magro C. Reactive arthritis following COVID-19 vaccination with BNT162b2. JAAD Case Rep. 2022;24:108-111.

Yuen CA, Hsu J-, Van Besien K, Reshef R, Iwamoto FM, Haggiagi A, et al. Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience. J Immunother. 2022;45(5):254-262.